Vaxart (VXRT) Projected to Post Quarterly Earnings on Monday

Vaxart (NASDAQ:VXRT - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The company had revenue of $15.19 million during the quarter, compared to the consensus estimate of $15.68 million. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Stock Up 4.9 %

NASDAQ VXRT opened at $0.45 on Monday. The stock's 50-day simple moving average is $0.43 and its two-hundred day simple moving average is $0.60. Vaxart has a twelve month low of $0.29 and a twelve month high of $1.07. The company has a market capitalization of $102.63 million, a price-to-earnings ratio of -1.10 and a beta of 1.27.

Analyst Upgrades and Downgrades

Separately, B. Riley lowered their price objective on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a report on Thursday, March 27th.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.